

Date: November 13, 2024

Listing Manager, National Stock Exchange of India Limited Exchange Plaza, 5 th Floor Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400051, India Symbol: PARKHOTELS ISIN No.: INE988S01028	BSE Limited Corporate Relationship Department 1 st Floor, New Trading Ring Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai – 400001, India Scrip Code: 544111 ISIN No.: INE988S01028
--	--

Subject: Newspaper Advertisement- Un-audited (Standalone and Consolidated) Financial Results for the second quarter (Q2) and half-year ended on September 30, 2024

Respected Sir/Ma'am,

Pursuant to Regulation 47 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copies of the newspaper advertisement published in The Economic Times (English) and in Ei Samay (Bangla) on Wednesday, November 13, 2024, relating to un-audited (Standalone and Consolidated) Financial Results for the second quarter (Q2) and half-year ended on September 30, 2024.

This will also be posted on the Company's website at <https://www.theparkhotels.com>.

This is for your information and records.

Thanking You

Yours Sincerely,

For Apeejay Surrendra Park Hotels Limited


Shalini Keshan

(Company Secretary and Compliance Officer)

Membership No.: ACS-014897



Encl: As above

EXPANSION OF BILATERAL AIR TREATIES

Boarding Soon: More Flights to Vietnam and Uzbekistan

Arindam Majumder

New Delhi: India has agreed to liberalise air treaty with Vietnam and Uzbekistan which will allow carriers from both countries to launch more flights.

People aware of the development said that the new agreement will allow Vietnamese carriers to increase flights from 28 flights to 42 flights per week while for Uzbekistan the quota has been increased from 14 to 28 flights per week.

The revisions are one of the rare instances where India has agreed to increase seats as expansion of bilateral rights has been a contentious issue, with the Narendra Modi government resisting calls to give more access to foreign carriers since it first took charge in 2014.

This, the government said, is aimed at protecting Indian airlines which don't have enough exposure on international routes and would easily be eclipsed by bigger global rivals.

Flying rights are allocated on a bilateral reciprocal basis by the government to airlines of their country. Airlines cannot operate more flights than they are allotted.

In March, India and Thailand agreed to similar revisions allowing airlines to hike capacity by 14,000 seats per week and launch new destinations.

Vietnamese carriers were unable to launch more flights between India's metro cities—Delhi, Mumbai, Hyderabad, Chennai and Kolkata—to Vietnam and the rights were exhausted with 14 each by Vietnam Airlines and VietJet.

However, under the India-ASEAN agreement, airlines of the country can launch unlimited flights to 18 other cities like Ahmedabad, Lucknow, and Bhubaneswar.

The extension will allow Vietnam Airlines and Vietjet to launch flights to Ho Chi Minh and Hanoi from Hyderabad and Bengaluru which they were unable to due to the exhaustion of capacity.

“Vietnam is a hot-selling destination from India driven by increase in flight connectivity. Vietnam Airlines with its A350 aircraft is the first full service carrier on the route which will appeal to the premium travellers,” Nguyen Trung Hieu, Vietnam Airlines country manager India had told ET.

Similarly, between India and Uzbekistan, IndiGo and Uzbekistan Airways operate flights between the two countries.

Pharma Mkt Sees 6.1% Growth in Oct Despite Subdued Volumes

Majority of growth driven by pricing, new launches: Data

Teena Thacker

New Delhi: The Indian pharmaceutical market posted a 6.1% value growth in October, led by therapies including cardiac and dermatology, even as sales volume dipped year-on-year, data from market research firm Pharmarack showed.

“Majority of the therapies are showing a positive growth, though unit growth continues to be a challenge for the current month (November),” said Shetal Sapale, vice president-commercial, Pharmarack.

The growth is driven price and new introductions while most therapies have seen a drop in volumes, she said.

Amongst the top 10 therapies that contribute to more than 90% of the Indian pharma market, price drove growth in the cardiac segment. The anti-hy-

Imbalanced Growth

- Majority of therapies show positive growth
- Cardiac Segment
 - Price has driven growth of market
 - In anti-hypertensives, volume growth is stagnated
- Diabetes Segment
 - Many products have lost patents
 - New launches drive the growth
 - In Anti diabetes, the OED combinations have shown negative volume growth
- Gynaecological Section
 - Hormones brought down volume growth
 - New launches pushed growth of market

pertensives, which account for almost 50% of the cardiac segment, is experiencing stagnated volume growth. Lipid-lowering drugs and platelet aggregation inhibitors have shown a relatively higher growth to help boost the cardiac segment.


In the anti-infective segment, antibacterials—which contribute to almost 87%—have brought down the volumes. Antifungals, on the other hand, have grown in volumes.

Antacids, which contribute to almost 40% of the gastro segment, have seen a fall in sales volume whereas laxatives, probiotics, anti-infectives and anti-diarrheal have shown volume growth. “These are the ones which have pushed up the volume growth whereas the antacids are the ones which have pulled down the growth of the segment,” Sapale said.

In the anti-diabetes segment, the oral anti-diabetics combinations have shown a negative volume growth while a good amount of growth is seen to be coming through new introductions as many products have lost patents, Pharmarack data

suggests.

Vitamins and nutraceuticals, which collectively contribute to 70% of the nutrition market, have shown a fall in volumes, pushing down growth of this segment. Calcium products and others, too, posted a fall but their contribution to the nutritionist category is lesser.

<div> JAI BALAJI INDUSTRIES LIMITED</div>													
Registered Office : 5, Bentinck Street, Kolkata - 700001													
Phone : (033) 2248-9808, Fax : (033) 2243-0021													
Email : jaibalaji@jaibalajigroup.com, Website : www.jaibalajigroup.com													
CIN : L27102WB1999PLC089755													
EXTRACT OF STATEMENT OF UN-AUDITED FINANCIAL RESULTS FOR THE SECOND QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2024													
(₹ in Crores)													
Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Six Months Ended			Quarter Ended			Six Months Ended		
		Year Ended											
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024	30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.23	31.03.2024
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Total income from operations	1,578.52	1,727.81	1,574.22	3,306.33	3,064.61	6,628.87	1,578.52	1,727.81	1,574.22	3,306.33	3,064.61	6,628.87
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	212.74	287.29	201.55	500.03	371.98	963.21	212.74	287.29	201.55	500.03	371.98	963.21
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items)	212.74	287.29	201.55	500.03	371.98	963.21	212.74	287.29	201.55	500.03	371.98	963.21
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	153.16	208.82	201.55	361.98	371.98	879.56	153.16	208.82	201.55	361.98	371.98	879.56
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax))	153.16	208.82	201.55	361.98	371.98	878.75	153.16	208.82	201.55	361.98	371.98	878.75
6	Equity Share Capital	182.45	177.45	160.45	182.45	160.45	163.65	182.45	177.45	160.45	182.45	160.45	163.65
7	Other Equity	-	-	-	-	-	1,340.47	-	-	-	-	-	1,340.47
8	Earnings Per Share (EPS) (of ₹ 10/- each) (not annualised)												
	(a) Basic (in ₹)	8.42	12.10	12.79	20.42	24.13	55.80	8.42	12.10	12.79	20.42	24.13	55.80
	(b) Diluted (in ₹)	8.42	11.76	11.22	20.42	20.83	49.82	8.42	11.76	11.22	20.42	20.83	49.82
NOTE:													
a) The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges for the second quarter & half year ended 30th September, 2024 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results for the second quarter & half year ended 30th September, 2024 are available on the Stock Exchange websites viz. www.nseindia.com, www.bseindia.com and on the Company's Website.													
b) The above Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 12.11.2024.													
c) Figures for the previous period/year have been re-grouped/re-arranged wherever necessary, to make them comparable.													
FOR JAI BALAJI INDUSTRIES LIMITED													
sd/-													
Aditya Jajodia													
(Chairman & Managing Director)													
(DIN : 00045114)													
Place : Kolkata													
Date : 12th November, 2024													

Uno Minda Limited

(Formerly known as Minda Industries Ltd.)
(CIN: L74899DL1992PLC050333)
REGD. OFFICE: B-64/1, Wazirpur Industrial Area, Delhi-110052
CORP. OFFICE: Village Nawada Fatehpur, P. O. Sikandarpur Badda, Near IMT Manesar, Gurgaon (Haryana) - 122004
Tel.: +91 124 2290427/28, 2290693/94/96
E-mail: investor@unominda.com, Website: www.unominda.com

EXTRACTS OF THE CONSOLIDATED & STANDALONE UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2024

(₹ In Crores)										(₹ In Crores)									
Consolidated						PARTICULARS	Standalone												
Quarter Ended		Half Year Ended		Year Ended	Quarter Ended		Half Year Ended		Year Ended										
30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024		30-09-2024	30-06-2024	30-09-2023	30-09-2024	30-09-2023	31-03-2024							
Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited							
4244.79	3,817.51	3,621.30	8,062.30	6,713.96	14,030.89	1	Total income from Operations	2693	2451.55	2300.88	5144.55	4246.87	8983.30						
336.07	277.47	311.05	613.54	535.08	1,165.21	2	Net Profit/ (Loss) for the period (before Tax, Exceptional and/or Extra-Ordinary items)	310.97	158.96	218.32	469.93	375.05	730.32						
344.61	277.47	311.05	622.08	535.08	1,191.83	3	Net Profit/ (Loss) for the period before Tax (after Exceptional and/or Extra-Ordinary items)	310.97	158.96	218.32	469.93	375.05	730.32						
266.16	210.80	237.71	476.96	417.88	924.71	4	Net Profit/ (Loss) for the period after Tax (after Exceptional and/or Extra-Ordinary items)	275.56	122.96	176.34	398.52	311.50	585.83						
256.69	199.84	212.26	456.53	369.94	886.78	5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income(after tax))	256.49	113.92	151.25	370.41	267.84	538.01						
114.83	114.83	114.63	114.83	114.63	114.82	6	"Paid up Equity Share Capital (Face Value Rs. 2 per share)"	114.83	114.83	114.63	114.83	114.63	114.82						
-	-	-	-	-	4827.95	7	"Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of Previous Year)"	-	-	-	-	-	3690.67						
						8	"Earnings Per Share (face value of Rs. 2 each) (for continuing and discontinuing operations) (not annualised)."												
4.27	3.47	3.93	7.74	6.94	15.36	a)	Basic EPS (in Rs.)	4.80	2.14	3.03	6.94	5.38	10.22						
4.26	3.46	3.92	7.72	6.93	15.34	b)	Diluted EPS (in Rs.)	4.79	2.13	3.02	6.92	5.37	10.21						

Additional Information on Standalone Financial Results :				(₹ In Crores)	
S. No.	PARTICULARS	Quarter Ended		Year Ended	
		30-09-2024	30-09-2023	31-03-2024	
		Un-Audited	Un-Audited	Audited	
1.	Securities Premium Account	1462.98	1405.08	1460.96	
2.	Net worth	4107.64	3509.74	3805.49	
3.	Outstanding Debt	1324.28	765.79	925.60	
4.	Debt Equity Ratio	0.34	0.23	0.25	
5.	Capital Redemption Reserve	18.39	18.39	18.39	
6.	Debt Service Coverage Ratio	4.73	4.55	6.27	
7.	Interest Service Coverage Ratio	12.64	16.88	14.47	

Notes:-

1) The Standalone and Consolidated Un-Audited Financial Results for the quarter and half year ended on September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on November 12, 2024.

2) The above is an extract of the detailed format of the financial results of the company for the quarter and half year ended on September 30, 2024 filed with stock exchanges pursuant to Regulation 33 & 52 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of both these results (standalone and consolidated) are available on the stock exchange website(s) NSE website (www.nseindia.com), BSE website (www.bseindia.com) and on Company's website (www.unominda.com).

3) For the other line items referred in regulation 52(4) of the Listing Regulations, pertinent disclosures have been made to the Stock Exchange(s) (NSE & BSE) and can be accessed on the NSE website (www.nseindia.com), BSE website (www.bseindia.com) and on Company's website (www.unominda.com).



For and on behalf of the Board of
Uno Minda Limited

NIRMAL K. MINDA
Chairman & Managing Director
DIN: 00014942

Place : Gurgaon (Haryana)
Date : November 12, 2024

Follow us on:

"Uno Minda Limited is a flagship company of UNO MINDA Group. The Group is a Tier 1 Auto Component Supplier to all leading OEMs in India and across the Globe. It manufactures Automotive Switches, Lamps, Batteries, Horns, CNG/LPG Kits, Fuel Caps, Electronic Components, Alloy Wheels, Die Casting and Blow Moulding Components."



APEEJAY SURRENDRA PARK HOTELS

APEEJAY SURRENDRA PARK HOTELS LIMITED

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2024

(Rs. in crores, unless otherwise stated)

S. No.	Particulars	Quarter ended			Six months ended		Year ended
		30.09.2024	30.06.2024	30.09.2023*	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Audited)
I	Total income	156.33	138.23	141.49	294.56	272.31	591.71
II	Profit before Finance costs, Depreciation and amortisation expense and Tax	56.33	41.69	50.89	98.02	90.90	205.24
III	Profit before tax for the period/year	38.92	24.61	21.43	63.53	33.63	88.66
IV	Profit/(Loss) after tax for the period/year	26.76	(1.91)	14.82	24.85	22.94	68.77
V	Total comprehensive Income/(loss) for the period/year, net of tax	27.97	(2.35)	14.59	25.61	22.41	67.01
VI	Paid-up Equity Share Capital (Face value per share - Re. 1 each)	21.34	21.34	17.47	21.34	17.47	21.34
VII	Other equity	-	-	-	-	-	1,176.65
VIII	Earnings/(loss) per equity share of face value of Re.1 each attributable to equity holders of the parent (EPS)						
	Basic (Rs.)	1.25	(0.09)	0.85	1.16	1.31	3.82
	Diluted (Rs.)	1.25	(0.09)	0.85	1.16	1.31	3.82
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

